Tag: 1334177-86-4

1334177-86-4, 1-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3-oxo-7,10,13,16,19,22,25,28-octaoxa-4-azahentriacontan-31-oic acid is a pyrrolines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

EDCI.HCI (0.13 g, 0.66 mmol, 1.1 eq.) was added to a cloudy solution of compound 21(0.61 g, 0.6 mmol, 1.0 eq.) and Mal-dPEG8-OH (0.393 g, 0.66 mmol, 1.1 eq.) in CHCI3(25 mL). The clear solution was stirred at room temperature for 1 .5h., diluted with CHCI3(100 mL) washed with brine (2 x 100 mL), dried (Mg504) and evaporated under reducedpressure to give a yellow foam. Purification by flash column chromatography [CHCI3/MeOH0% to 6% in 1% increments gave the product as a white foam (0.786 g, 82%). AnalyticalData: RT 1.44 mm; MS (ES) m/z (relative intensity) 1586 ([M + H],40), 1609 ([M + Na],100)

1334177-86-4, The synthetic route of 1334177-86-4 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; ADC THERAPEUTICS SA; MEDIMMUNE LIMITED; VAN BERKEL, Patricius Hendrikus Cornelis; HOWARD, Philip Wilson; DUNNY, Elizabeth; HUTCHINSON, Ian; MASTERSON, Luke; (73 pag.)WO2017/137556; (2017); A1;,
Pyrroline – Wikipedia
1-Pyrroline | C4H7N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1334177-86-4,1-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3-oxo-7,10,13,16,19,22,25,28-octaoxa-4-azahentriacontan-31-oic acid,as a common compound, the synthetic route is as follows.

(e) N-((S)- 1-(((S)- 1-((4-((S)-8-(3-(((S)-2-(Benzo[d][1, 3]dioxol-5-yl)-7-methoxy-5-oxo-5, 11a- dihydro-1H-pyrrolo[2, 1-c][1,4]benzodiazepin-8-yl)oxy)propoxy)-7-methoxy-5-oxo-5, 11a- dihydro-1H-pyrrolo[2, 1-c][1,4]benzodiazepin-2-yl)phenyl)amino)-1-oxopropan-2-yl)amino)-3- methyl- 1 -oxobutan-2-yl)- 1-(3-(2, 5-dioxo-2, 5-di hydro- 1H-pyrrol- 1 -yl)propanamido)- 3,6,9, 12, 15, 18,21 ,24-octaoxaheptacosan-27-amide (33) The imine 32 (92 mg, 0.1 mmol, 1.1 equiv.) was dissolved in CHCI3 (6 mL) with one drop of anhydrous MeOH to aid dissolution. Maleimide-PEG8-acid (53 mg, 0.09 mmol, 1 equiv.) was added followed by EEDQ (33 mg, 0.14 mmol, 1 .5 equiv.). This was left to stir vigorously at room temperature under Ar for 4 days until LC/MS analysis showed majority product formation. The solvent was removed in vacuo and the crude product was partially purified by silica gel column chromatography (CHCI3 with 1 % to 10% MeOH gradient) yielding 33 (81 mg). The material was purified further by preparative HPLC to give 33 as a yellow solid (26.3 mg, 18%). Fast Formic run: LC/MS (1.39 min (ES+) m/z (relative intensity) 1485.00 ([M + H]+., 64).

1334177-86-4, 1334177-86-4 1-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3-oxo-7,10,13,16,19,22,25,28-octaoxa-4-azahentriacontan-31-oic acid 51340955, apyrrolines compound, is more and more widely used in various.

Reference£º
Patent; SPIROGEN SARL; HOWARD, Philip Wilson; WO2014/57073; (2014); A1;,
Pyrroline – Wikipedia
1-Pyrroline | C4H7N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1334177-86-4,1-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3-oxo-7,10,13,16,19,22,25,28-octaoxa-4-azahentriacontan-31-oic acid,as a common compound, the synthetic route is as follows.

EDCI hydrochloride (39 mg, 0.197 mmol, leq.) was added to a suspension of maleimide-PEG8-acid (117 mg, 0.197 mmol, leq.) in dry CH2CI2 (5 mL) under argon atmosphere. The mixture was stirredfor 30 mm at room temperature before PBD 13 (250 mg, 0.197 mmol) was added. Stirring was maintained until the reaction was complete (usually 5 hours). The reaction was diluted with CH2CI2 and the organic phase was washed with H20 and brine before being dried over Mg504, filtered and excess solvent removed by rotary evaporation under reduced pressure. The product was purified by careful silica gel chromatography (gradient elution: 100% CHCI3 to 9:1 v/v CHCI3/MeOH)to affordpure product 14(273.8mg, 75% yield). Analytical data: ES = 1.99 mi m/z 1863.95 [M+Na].

1334177-86-4, As the paragraph descriping shows that 1334177-86-4 is playing an increasingly important role.

Reference£º
Patent; MEDIMMUNE LIMITED; HOWARD, Philip Wilson; CAILLEAU, Thais; (159 pag.)WO2017/129652; (2017); A1;,
Pyrroline – Wikipedia
1-Pyrroline | C4H7N – PubChem

1334177-86-4, 1-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3-oxo-7,10,13,16,19,22,25,28-octaoxa-4-azahentriacontan-31-oic acid is a pyrrolines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Chloroform (4.1 ml) and methanol (0.2 ml) were added to 23, followed by mal-amidopeg8-acid (238 mg, 0.394 mmol, 2.2 eq) and EDCI (85.0 mg, 0.443 mmol, 2.48 eq). The reaction was allowed to proceed at room temperature for 45 min when completion was observed by LCMS. The reaction mixture was concentrated (2 ml), loaded on a 3g biotage 20 silica samplet and dried under vacuum. The samplet was loaded on a 25g Ultra Biotage column, and eluted (gradient 10/90 to 58/42 of 20% MeOH in DCM I DCM in 12CV; Elution at around 55% of 20% MeOH). All fractions were analysed by TLC (10% MeOH in DCM). The pure fractions were pooled. The solvent was removed by evaporation to give 24 (250 mg, 0.105 mmol, 58.8% Yield). Analytical Data: LC/MS, 15 min method, RT 6.20 min; MS 25 (ES+) m/z (relative intensity) 1191.5 ([M + 2Hf+¡¤, 1 00); 1H NMR (400 MHz, DMSO-d6) o 9.92 (s, 2H), 8.16 (d, J = 6.9 Hz, 2H), 7.99 (t, J = 5.5 Hz, 2H), 7.86 (d, J = 8.6 Hz, 2H), 7.68 – 7.42 (m, 4H), 7.39- 7.11 (m, 4H), 7.07 (s, 2H), 7.00 (s, 4H), 6.81 (s, 2H), 6.60 (s, 2H), 5.46- 5.30 (m, 2H), 5.21 -4.79 (m, 8H), 4.39 (t, J = 7.0 Hz, 2H), 4.22 (dd, J = 8.7, 6.7 Hz, 2H), 4.15- 3.88 (m, 8H), 3.77 (s, 6H), 3.65- 3.55 (m, 8H), 3.54- 3.40 (m, 58H), 3.37 (t, J 30 = 5.9 Hz, 4H), 3.15 (q, J = 5.8 Hz, 4H), 2.95-2.79 (m, 2H), 2.57-2.52 (m, 2H), 2.492.37 (m, 4H), 2.37-2.29 (m, 4H), 2.22-2.10 (m, 2H), 2.03- 1.88 (m, 2H), 1.30 (d, J = 7.0 Hz, 6H), 0.85 (dd, J = 15.3, 6.7 Hz, 12H)., 1334177-86-4

As the paragraph descriping shows that 1334177-86-4 is playing an increasingly important role.

Reference£º
Patent; MEDIMMUNE LIMITED; DIMASI, Nazzareno; HOWARD, Philip Wilson; MASTERSON, Luke; TIBERGHIEN, Arnaud Charles; VIJAYAKRISHNAN, Balakumar; WHITE, Jason; (135 pag.)WO2019/34764; (2019); A1;,
Pyrroline – Wikipedia
1-Pyrroline | C4H7N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1334177-86-4,1-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3-oxo-7,10,13,16,19,22,25,28-octaoxa-4-azahentriacontan-31-oic acid,as a common compound, the synthetic route is as follows.

(e) 1-(3-(2, 5-dioxo-2 , 5-dihydro- 1H-pyrrol- 1-yI)propanamido)-N-((2S)- 1-(((2S) – 1-((4-(7- methoxy-8-(3-((7-methoxy-2-(4-(4-methylpiperazin- 1-yI)phenyl)-5-oxo-5, 1 la-dihydro- 1H- benzo[e]pyrrolo[1, 2-a][1, 4]diazepin-8-yI) oxy)propoxy) -5-oxo-5, 1 la-dihydro- 1H- benzo[e]pyrrolo[1, 2-a][1, 4]diazepin-2-yI)phenyl)amino) – 1-oxopropan-2-yI)amino)-3-methyl- 1- oxobutan-2-yI)-3, 6,9, 12,15, 18,21, 24-octaoxaheptacosan-2 7-amide (86)EDCI hydrochloride (8 mg, 0.042 mmol) was added to a suspension of Maleimide-PEG8-acid (25 mg, 0.042 mmol) in dry CH2CI2 (4 mL) under argon atmosphere. PBD 85 (42 mg, crude) was added straight away and stirring was maintained until the reaction was complete (3 hours). The reaction was diluted with CH2CI2 and the organic phase was washed with H20 and brine before being dried over MgSO4, filtered and excess solvent removed by rotary evaporation under reduced pressure by rotary evaporation under reduced pressure. The product was purified by careful silica gel chromatography (slow elution starting with 100% CHCI3 up to 9:1 CHCI3/MeOH) followed by reverse phase HPLC to remove unreacted maleimide-PEG8-acid. The product 86 was isolated in 10% over two steps (6.6 mg). LC/MS 1.16 mm (ES+) m/z (relative intensity) 770.20 ([M+ 2H], 40%)., 1334177-86-4

1334177-86-4 1-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3-oxo-7,10,13,16,19,22,25,28-octaoxa-4-azahentriacontan-31-oic acid 51340955, apyrrolines compound, is more and more widely used in various.

Reference£º
Patent; CANCER RESEARCH TECHNOLOGY LIMITED; VAN BERKEL, Patricius Henrikus Cornelis; HOWARD, Philip Wilson; WILLIAMS, David G; WO2015/159076; (2015); A1;,
Pyrroline – Wikipedia
1-Pyrroline | C4H7N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1334177-86-4,1-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3-oxo-7,10,13,16,19,22,25,28-octaoxa-4-azahentriacontan-31-oic acid,as a common compound, the synthetic route is as follows.

DCM (10.00 ml) and methanol (0.4 ml) were added to 36 (393 mg, 0.305 mmol), followed by mal-amido-peg8-acid (380 mg, 0.628 mmol, 2.06 eq) and EDCI (128 mg, 0.668 mmol, 2.2 eq). The reaction was allowed to proceed at room temperature for 4h when completion 15 was observed by LCMS. Ammonium chloride in water (30 ml, 6 mass%) was added and the mixture was stirred vigorously. The mixture was decanted in a biotage phase separation cartridge. The DCM layer was evaporated to dryness under vacuum and the crude residue was purified by chromatography (25g Ultra gradient 15/85 to 100/0 of 20% MeOH in DCM I DCM in 12CV; hold at elution around 48%). The fractions were analysed 20 by TLC (1 0% MeOH in DCM). The pure fractions were pooled. The solvent was removed by evaporation. The residue was purified further by reverse phase preparative HPLC (gradient 15 to 75% water/acetonitrile + 0.01% formic acid) followed by freeze-drying and aliquoted from DCM to give 37 (516 mg, 0.212 mmol, 69.4% Yield) as a white foam. The purity was 97.65%. Analytical Data: LC/MS, 15 min method, RT 6.61 min; MS (ES+) m/z 25 (relative intensity) 1219.7 ([M + 2Hf+¡¤, 100); 1H NMR (400 MHz, DMSO-d6) o 9.92 (s, 2H), 8.17 (d, J = 6.9 Hz, 2H), 8.01 (t, J = 5.6 Hz, 2H), 7.87 (d, J = 8.7 Hz, 2H), 7.72- 7.44 (m, 4H), 7.39- 7.10 (m, 4H), 7.05 (s, 2H), 7.00 (s, 4H), 6.76 (s, 2H), 6.66- 6.46 (m, 2H), 5.56 (d, J = 7.1 Hz, 2H), 5.34 (dd, J = 9.7, 5.9 Hz, 2H), 5.21 – 4.70 (m, 4H), 4.39 (t, J = 7.0 Hz, 2H), 4.22 (dd, J = 8.7, 6.7 Hz, 2H), 4.15-4.01 (m, 2H), 3.94 (d, J = 15.3 Hz, 4H), 3.8630 3.72 (m, 8H), 3.60 (t, J = 7.3 Hz, 8H), 3.55- 3.42 (m, 58H), 3.37 (t, J = 5.9 Hz, 4H), 3.15 (q, J = 5.8 Hz, 4H), 2.76-2.56 (m, 4H), 2.46 (t, J = 6.8 Hz, 2H), 2.40 (t, J = 6.5 Hz, 2H), 2.36- 2.29 (m, 4H), 1.96 (q, J = 6.7 Hz, 2H), 1.78 (s, 4H), 1.66 (d, J = 6.6 Hz, 6H), 1.57 (d, J = 8.6 Hz, 2H), 1.30 (d, J = 7.0 Hz, 6H), 0.85 (dd, J = 15.2, 6.7 Hz, 12H)., 1334177-86-4

The synthetic route of 1334177-86-4 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; MEDIMMUNE LIMITED; DIMASI, Nazzareno; HOWARD, Philip Wilson; MASTERSON, Luke; TIBERGHIEN, Arnaud Charles; VIJAYAKRISHNAN, Balakumar; WHITE, Jason; (135 pag.)WO2019/34764; (2019); A1;,
Pyrroline – Wikipedia
1-Pyrroline | C4H7N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1334177-86-4,1-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3-oxo-7,10,13,16,19,22,25,28-octaoxa-4-azahentriacontan-31-oic acid,as a common compound, the synthetic route is as follows.

N-(3-Dimethylaminopropyl)-N?-ethylcarbodiimide (28 mg, 0.146 mmol, I eq) was added to asolution of 42 (203 mg, 0.146 mmol) and maleimide-PEG8 acid (87 mg, 0.146 mmol) inchloroform (5 mL). The reaction was stirred for 1.5 h then diluted with chloroform (50 mL), washed with water (50 mL), brine (30 mL), dried over magnesium sulphate, filtered and evaporated. Flash chromatography [gradient elution 100% DCM to 90% DCM/I0% methanol] gave 43 as a pale yellow solid (205 mg, 72%). LC/MS: RT 5.75 mm; MS (ES+)m/z (relative intensity) 982.90 (100), 1963.70 (5)., 1334177-86-4

The synthetic route of 1334177-86-4 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; SPIROGEN SARL; ADC THERAPEUTICS SARL; HOWARD, Philip Wilson; VAN BERKEL, Patricius Hendrikus Cornelis; WO2015/52532; (2015); A1;,
Pyrroline – Wikipedia
1-Pyrroline | C4H7N – PubChem

1334177-86-4, 1-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3-oxo-7,10,13,16,19,22,25,28-octaoxa-4-azahentriacontan-31-oic acid is a pyrrolines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

EDCI hydrochloride (8 mg, 0.042 mmol) was added to a suspension of Maleimide-PEG8-acid (25 mg, 0.042 mmol) in dry CH2Cl2 (4 mL) under argon atmosphere. PBD 85 (42 mg, crude) was added straight away and stirring was maintained until the reaction was complete (3 hours). The reaction was diluted with CH2Cl2and the organic phase was washed with H2O and brine before being dried over MgS04, filtered and excess solvent removed by rotary evaporation under reduced pressure by rotary evaporation under reduced pressure. The product was purified by careful silica gel chromatography (slow elution starting with 100% CHCI3 up to 9:1 CHCl3/MeOH) followed by reverse phase HPLC to remove unreacted maleimide-PEG8-acid. The product 86 was isolated in 10% over two steps (6.6 mg). LC/MS 1 .16 min (ES+) m/z (relative intensity) 770.20 ([M + 2H]+ , 40%).

1334177-86-4, 1334177-86-4 1-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3-oxo-7,10,13,16,19,22,25,28-octaoxa-4-azahentriacontan-31-oic acid 51340955, apyrrolines compound, is more and more widely used in various.

Reference£º
Patent; VAN BERKEL, Patricius Hendrikus Cornelis; HOWARD, Philip Wilson; (308 pag.)WO2016/166304; (2016); A1;,
Pyrroline – Wikipedia
1-Pyrroline | C4H7N – PubChem

1334177-86-4, 1-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3-oxo-7,10,13,16,19,22,25,28-octaoxa-4-azahentriacontan-31-oic acid is a pyrrolines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

(d) (ii S, i ia S)-4-((2S, 5S)-37-(2, 5-di oxo-2, 5-dihydro- iH-pyrrol- i-yl)-5-isopropyl-2-methyl- 4,7, 35-trioxo- 10, 13,16, 19,22,25,28,3 i-octaoxa-3, 6, 34-triazaheptatriacontanamido)benzyl iihydroxy- 7-methoxy-8-((5-(((S) – 7-methoxy-2-methyl-5-oxo-5, i ia-dihydro- iHbenzo[e]pyrrolo[i, 2-a][i, 4]diazepin-8-yl) oxy) pentyl) oxy) -2-met hyl-5-oxo- 11,1 ia-dihydro- iHbenzo[e]pyrrolo[i, 2-a][i, 4]diazepine- i 0(5H)-carboxylate (64) 1-ethyl-3-(3?-dimethylaminopropyl)carbodiimide (EDCI, 33 mg, 0.172 mmol) was added to a solution of crude 63 (0.172 mmol) and Mal-(PEG)8-acid (100 mg, 0.172 mmol) in dry dichloromethane (10 mL). The reaction was stirred for 2 hours and the presence ofstarting material was no longer observed by LC/MS. The reaction was diluted with dichloromethane and washed sequentially with water and brine. The organic phase was dried over magnesium sulphate filtered and excess dichloromethane removed by rotary evaporation under reduced pressure. The resulting residue was subjected to flash column chromatography (silica gel; 100% chloroform to 10% methanol in chloroform). Pure fractions were collected and combined and excess eluent was removed by rotary evaporation under reduced pressure to give 64 (E) (60 mg, 25% over 3 steps).

1334177-86-4, As the paragraph descriping shows that 1334177-86-4 is playing an increasingly important role.

Reference£º
Patent; CANCER RESEARCH TECHNOLOGY LIMITED; VAN BERKEL, Patricius Henrikus Cornelis; HOWARD, Philip Wilson; WILLIAMS, David G; WO2015/159076; (2015); A1;,
Pyrroline – Wikipedia
1-Pyrroline | C4H7N – PubChem

1334177-86-4, 1-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3-oxo-7,10,13,16,19,22,25,28-octaoxa-4-azahentriacontan-31-oic acid is a pyrrolines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Procedure: Bromine (0.20 ml, 3.88 mmol) was added to a solution of 1 – (2,5-dioxo-2,5-dihydro-1 H-pyrrol-1 -yl)-3-oxo-7,10,13,16,19,22,25,28-octaoxa-4- azahentriacontan-31 -oic acid (1000 mg, 1 .69 mmol) in methylene chloride (17 ml). After stirring for 14 h, the solution was cooled to -10C in an ice/brine bath and diisopropylethylamine (1 .5 ml, 8.61 mmol) was slowly added dropwise. After stirring for an additional 24 h, during which time the solution warmed to ambient temperature, the solution was concentrated under reduced pressure to afford crude 1 -(3-bromo- 2,5-dioxo-2,5-dihydro-1 H-pyrrol-1 -yl)-3-oxo-7,10,13,16,19,22,25,28-octaoxa-4- azahentriacontan-31 -oic acid. UPLC/MS 1 .18 min (5-95% acetonitrile/water + 0.1 % formic acid over 2 min, hold at 95% for 0.5 min, then 95-5% over 0.1 min, and hold at 5% for 0.4 min. Column used was Waters BEH C18 1 .7 muiotatauiota, 2.1 x 50 mm, flow rate was 0.8 mL/min.), m/z 671 .6 and 673.6 [M+H]+.

1334177-86-4, 1334177-86-4 1-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3-oxo-7,10,13,16,19,22,25,28-octaoxa-4-azahentriacontan-31-oic acid 51340955, apyrrolines compound, is more and more widely used in various.

Reference£º
Patent; IGENICA BIOTHERAPEUTICS, INC.; JACKSON, David, Y.; HA, Edward; SAUER, Paul; BOWERS, Simeon; BRUHNS, Maureen, Fitch; MONTEON, Jorge; BEHRENS, Christopher; HALCOMB, Randall, L.; (281 pag.)WO2016/64749; (2016); A2;,
Pyrroline – Wikipedia
1-Pyrroline | C4H7N – PubChem